Alnylam to Webcast Conference Call Discussing Second Quarter 2017 Financial Results
August 01 2017 - 4:00PM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading
RNAi therapeutics company, announced today that it will report
financial results for the second quarter ending June 30, 2017 on
Wednesday, August 9, 2017, after the U.S. financial markets
close.
Management will provide an update on the company and discuss
second quarter 2017 results as well as expectations for the future
via conference call on Wednesday, August 9, 2017 at 4:30 p.m. ET.
To access the call, please dial 877-312-7507 (domestic) or
631-813-4828 (international) five minutes prior to the start time
and refer to conference ID 59171216. A replay of the call will be
available beginning at 7:30 p.m. ET on the day of the call. To
access the replay, please dial 855-859-2056 (domestic) or
404-537-3406 (international), and refer to conference ID
59171216.
A live audio webcast of the call will be available on the
Investors section of the company’s website, www.alnylam.com. An
archived webcast will be available on the Alnylam website
approximately two hours after the event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA
interference (RNAi) into a whole new class of innovative medicines
with the potential to transform the lives of patients who have
limited or inadequate treatment options. Based on Nobel
Prize-winning science, RNAi therapeutics represent a powerful,
clinically validated approach for the treatment of a wide range of
debilitating diseases. Founded in 2002, Alnylam is delivering on a
bold vision to turn scientific possibility into reality, with a
robust discovery platform and deep pipeline of investigational
medicines, including three product candidates that are in
late-stage development or will be in 2017. Looking forward, Alnylam
will continue to execute on its “Alnylam 2020” strategy of building
a multi-product, commercial-stage biopharmaceutical company with a
sustainable pipeline of RNAi-based medicines. For more information
about our people, science and pipeline, please visit
www.alnylam.com and engage with us on Twitter at @Alnylam.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170801006219/en/
Alnylam Pharmaceuticals, Inc.Investors and MediaChristine
Regan Lindenboom, 617-682-4340orInvestorsJosh Brodsky,
617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024